Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. (2021)

First Author: Madhi SA
Attributed to:  nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19 funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(21)00157-0

PubMed Identifier: 34416193

Publication URI: http://europepmc.org/abstract/MED/34416193

Type: Journal Article/Review

Volume: 8

Parent Publication: The lancet. HIV

Issue: 9

ISSN: 2352-3018